Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
06 juin 2022 07h30 HE
|
Alectos Therapeutics Inc.
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
18 mai 2022 08h17 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression
11 avr. 2022 13h41 HE
|
Clinical Ink
Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today—World Parkinson’s Day—announces research that strengthens its standing as a critical...
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
30 mars 2022 08h30 HE
|
Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
17 mars 2022 09h00 HE
|
JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
10 mars 2022 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
25 janv. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
19 août 2021 18h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
15 oct. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
20 juil. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...